NovaBridge Biosciences (NBP) Gains from Sales and Divestitures (2020 - 2025)
NovaBridge Biosciences (NBP) reported Gains from Sales and Divestitures of $910939.0 for Q4 2025, up 1038.04% on a QoQ basis from $80044.4 in Q4 2023.
NovaBridge Biosciences (NBP) has 5 years of Gains from Sales and Divestitures data on file, last reported at $910939.0 in Q4 2025.
- Quarterly Gains from Sales and Divestitures changed N/A year-over-year to $910939.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $910939.0 (changed N/A YoY) and the FY2025 annual result came in at $910939.0, changed N/A from the prior year.
- Gains from Sales and Divestitures improved to $910939.0 in Q4 2025 per NBP's latest filing, from $80044.4 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $910939.0 in Q4 2025 and bottomed at $80044.4 in Q4 2023.
- The 4-year median for Gains from Sales and Divestitures is $110297.8 (2021), against an average of $302894.7.
- The widest annual swing landed in 2021, when Gains from Sales and Divestitures soared 39.92%; it then declined 20.96% in 2023.
- Tracing NBP's Gains from Sales and Divestitures over 4 years: stood at $119328.0 in 2021, then decreased by 15.14% to $101267.6 in 2022, then declined by 20.96% to $80044.4 in 2023, then jumped by 1038.04% to $910939.0 in 2025.
- Per Business Quant, the three latest NBP Gains from Sales and Divestitures figures stand at $910939.0 (Q4 2025), $80044.4 (Q4 2023), and $101267.6 (Q4 2022).
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 910,939.00 |
| Dec 31, 2025 | 910,939.00 |
| Dec 31, 2023 | 80,044.42 |
| Dec 31, 2023 | 80,044.42 |
| Dec 31, 2022 | 101,267.56 |
| Dec 31, 2022 | 101,267.56 |
| Dec 31, 2021 | 119,328.01 |
| Dec 31, 2021 | 119,328.01 |
| Dec 31, 2020 | 85,284.89 |
| Dec 31, 2020 | 85,284.89 |